CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in

CDK4/CDK6 KIT D816V abemaciclib avapritinib drug-combinations midostaurin palbociclib ribociclib systemic mastocytosis targeted therapy

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
23 Jun 2022
Historique:
received: 31 12 2021
revised: 23 05 2022
accepted: 06 06 2022
entrez: 9 7 2022
pubmed: 10 7 2022
medline: 10 7 2022
Statut: epublish

Résumé

In most patients with advanced systemic mastocytosis (AdvSM), neoplastic mast cells (MC) express

Identifiants

pubmed: 35804842
pii: cancers14133070
doi: 10.3390/cancers14133070
pmc: PMC9264943
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : FWF Austrian Science Fund
ID : #F4704-B20
Organisme : Medical Scientific Fund of the Mayor of the City of Vienna
ID : 17015

Références

Front Oncol. 2019 Jul 23;9:666
pubmed: 31396487
Expert Opin Investig Drugs. 2019 Nov;28(11):989-1001
pubmed: 31612739
Leuk Res. 2001 Jul;25(7):543-51
pubmed: 11377679
PLoS One. 2012;7(8):e43090
pubmed: 22905207
Mol Pharm. 2019 Jul 1;16(7):3040-3052
pubmed: 31117741
Nat Med. 2021 Dec;27(12):2192-2199
pubmed: 34873345
Blood. 2015 Jan 1;125(1):90-101
pubmed: 25342715
Nat Rev Clin Oncol. 2016 Jul;13(7):417-30
pubmed: 27030077
Genes Chromosomes Cancer. 2018 May;57(5):252-259
pubmed: 29341334
Lancet Haematol. 2019 Dec;6(12):e638-e649
pubmed: 31676322
J Invest Dermatol. 1991 Mar;96(3 Suppl):2S-4S; discussion 4S, 60S-65S
pubmed: 16799601
Haematologica. 2007 Nov;92(11):1451-9
pubmed: 18024392
Leukemia. 2015 Jun;29(6):1223-32
pubmed: 25650093
Leuk Res. 2001 Jul;25(7):603-25
pubmed: 11377686
Leuk Res. 2003 Jul;27(7):635-41
pubmed: 12681363
Exp Hematol. 2003 Aug;31(8):686-92
pubmed: 12901973
Haematologica. 2013 Sep;98(9):1450-7
pubmed: 23539538
Haematologica. 2018 May;103(5):799-809
pubmed: 29439183
N Engl J Med. 2016 Nov 3;375(18):1738-1748
pubmed: 27717303
Breast Cancer Res. 2009;11(5):R77
pubmed: 19874578
Haematologica. 2011 May;96(5):672-80
pubmed: 21242189
FASEB J. 2014 Aug;28(8):3540-51
pubmed: 24760752
Clin Cancer Res. 2020 Jun 15;26(12):2997-3011
pubmed: 32086342
Ann Hematol. 2002 Dec;81(12):677-90
pubmed: 12483363
Cancer Res. 2019 May 1;79(9):2352-2366
pubmed: 30819666
Leuk Lymphoma. 2020 May;61(5):1075-1083
pubmed: 31876203
Acta Pharmacol Sin. 2021 Feb;42(2):171-178
pubmed: 32504067
Genomics Proteomics Bioinformatics. 2022 Jan 24;:
pubmed: 35085776
Haematologica. 2011 Mar;96(3):459-63
pubmed: 21134978
Eur J Haematol. 2015 Jun;94(6):474-90
pubmed: 25753531
Clin Cancer Res. 2014 Jul 15;20(14):3763-74
pubmed: 24850847
Adv Enzyme Regul. 1984;22:27-55
pubmed: 6382953
J Allergy Clin Immunol. 2020 Aug;146(2):356-366.e4
pubmed: 32437738
Cancer Res. 2019 Aug 15;79(16):4283-4292
pubmed: 31270078
Comput Struct Biotechnol J. 2015 Sep 25;13:504-13
pubmed: 26949479
Leukemia. 2019 Nov;33(11):2673-2684
pubmed: 30953030
Mol Cancer Ther. 2020 Aug;19(8):1575-1588
pubmed: 32546660
Cell. 1995 May 5;81(3):323-30
pubmed: 7736585
J Clin Invest. 1993 Oct;92(4):1736-44
pubmed: 7691885
Blood. 2003 Dec 15;102(13):4270-6
pubmed: 12933573
Blood. 2021 Apr 15;137(15):2070-2084
pubmed: 33512435
Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10560-4
pubmed: 7479840
PLoS One. 2014 Jan 21;9(1):e85362
pubmed: 24465546
Blood. 2014 Jul 3;124(1):111-20
pubmed: 24677542
Nat Med. 2021 Dec;27(12):2183-2191
pubmed: 34873347
Clin Cancer Res. 2015 Jul 1;21(13):2905-10
pubmed: 25941111
N Engl J Med. 2016 Jun 30;374(26):2530-41
pubmed: 27355533
Leukemia. 2019 May;33(5):1195-1205
pubmed: 30911112
Front Cell Dev Biol. 2015 Apr 09;3:16
pubmed: 25914884
Leuk Res. 1988;12(4):345-55
pubmed: 3131594
Mol Cancer Ther. 2004 Nov;3(11):1427-38
pubmed: 15542782
Semin Oncol. 2017 Dec;44(6):395-403
pubmed: 29935901
Cancer Treat Rev. 2016 Apr;45:129-38
pubmed: 27017286
Blood. 2013 Oct 3;122(14):2460-6
pubmed: 23958953
Blood. 2017 Mar 16;129(11):1420-1427
pubmed: 28031180
Clin Cancer Res. 2015 Mar 1;21(5):995-1001
pubmed: 25501126
Gastroenterology. 2010 May;138(5):1920-30
pubmed: 20100483
Drugs. 2020 Mar;80(4):433-439
pubmed: 32100250
Blood. 2017 Jan 19;129(3):371-382
pubmed: 27856463
Blood. 2020 Apr 16;135(16):1365-1376
pubmed: 32106312
Ann Oncol. 2017 Oct 1;28(10):2367-2376
pubmed: 28945834
Hematol Oncol Clin North Am. 2017 Aug;31(4):643-661
pubmed: 28673393
Thorax. 2020 Sep;75(9):754-763
pubmed: 32709610
Cancer Cell. 2020 Mar 16;37(3):340-353.e6
pubmed: 32109375
Haematologica. 2016 Oct;101(10):1133-1143
pubmed: 27694501
Leukemia. 2016 Feb;30(2):464-72
pubmed: 26349526
Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):127-136
pubmed: 30504301
EBioMedicine. 2019 Dec;50:111-121
pubmed: 31761618
J Clin Oncol. 2014 Oct 10;32(29):3264-74
pubmed: 25154823
Mol Cancer Ther. 2016 Oct;15(10):2273-2281
pubmed: 27496135
J Clin Oncol. 2017 Sep 1;35(25):2875-2884
pubmed: 28580882
Clin Cancer Res. 2015 Nov 1;21(21):4760-6
pubmed: 26324739
Blood. 2006 Jan 15;107(2):752-9
pubmed: 16189265

Auteurs

Mathias Schneeweiss-Gleixner (M)

Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria.
Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria.
Department of Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, 1090 Vienna, Austria.

Yüksel Filik (Y)

Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria.
Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria.

Gabriele Stefanzl (G)

Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria.

Daniela Berger (D)

Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria.

Irina Sadovnik (I)

Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria.
Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria.

Karin Bauer (K)

Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria.
Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria.

Dubravka Smiljkovic (D)

Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria.
Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria.

Gregor Eisenwort (G)

Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria.
Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria.

Nadine Witzeneder (N)

Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria.

Georg Greiner (G)

Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria.
Department of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria.
Ihr Labor, Medical Diagnostic Laboratories Vienna, 1220 Vienna, Austria.

Gregor Hoermann (G)

Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria.
MLL Munich Leukemia Laboratory, 81377 Munich, Germany.

Ana-Iris Schiefer (AI)

Department of Pathology, Medical University of Vienna, 1090 Vienna, Austria.

Juliana Schwaab (J)

Department of Hematology and Oncology, University Medical Center Mannheim and Medical Faculty Mannheim, Heidelberg University, 69120 Heidelberg, Germany.

Mohamad Jawhar (M)

Department of Hematology and Oncology, University Medical Center Mannheim and Medical Faculty Mannheim, Heidelberg University, 69120 Heidelberg, Germany.

Andreas Reiter (A)

Department of Hematology and Oncology, University Medical Center Mannheim and Medical Faculty Mannheim, Heidelberg University, 69120 Heidelberg, Germany.

Wolfgang R Sperr (WR)

Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria.
Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria.

Michel Arock (M)

Department of Hematological Biology, Pitié-Salpêtrière Hospital, Pierre et Marie Curie University (UPMC), 75013 Paris, France.

Peter Valent (P)

Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria.
Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria.

Karoline V Gleixner (KV)

Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria.
Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria.

Classifications MeSH